Clinical evidence that immunogenic cell death sensitizes to PD-1/PD-L1 blockade

Abstract

In preclinical in vivo models of cancer, the induction of immunogenic cell death (ICD) sensitizes to subsequent immunotherapy. Several clinical trials now confirm that pretreatment with ICD-inducing anthracyclines sensitizes to immune checkpoint blockade targeting PD-1 and PD-L1 interaction. These findings support the translational utility of the concept of ICD.

Keywords

• anthracyclins
• immunogenic cell death
• pd-1
• pd-l1